Prostate cancer metastasis

Pharmatest prostate cancer metastasis models are suitable for testing the efficacy of drug compounds against several dissemination processes and growth in specific microenviroments. The metastasis models are demanding for the drug candidate, but exhibit excellent clinical predictivity.

Description

Pharmatest offers two types of translational prostate cancer metastasis models:

• The experimental intratibial xenograft models are clinically predictive models of cancer-induced bone disease that develop osteoblastic bone metastases with at least 70 per cent tumor incidence.
• The spontaneously metastasizing orthotopic model in turn develops lymph node metastases with at least 75 per cent incidence.

In the bone metastasis model radiography reveals the progression of the bone metastases. The data is analyzed for lesion area. When AR+ cell lines are used, radiography reveals the osteoblastic bone metastases typical for prostate cancer, and progression of the disease can be followed by serum PSA measurements.

Histological bone samples can be analyzed for tumor area, trabecular bone area and osteoclast number to reveal detailed information about the test compound’s effects on bone metastases.

Where the focus is on cancer bone metastases, researchers should also consider Pharmatest’s in vitro bone cell assays, which are useful for testing novel cancer drug compounds, especially those targeting the vicious cycle of cancer-induced bone disease.

Resources

Click on prostate cancer metastasis models for other information.
Click on Pharmatest to contact the company directly.

Supplier Information
Supplier: Pharmatest Services Ltd
Address: Itäinen Pitkäkatu 4 C, 5th floor, 20520 Turku, Finland
Tel: +358 2 278 4700
Fax: +358 2 278 4710
Website: www.pharmatest.com